RSC Safety Information Center (RIC) Frequently Asked Questions

How do I get on the list to receive safety information such as Safety Reports, Investigator's Brochures (IB) and Package Insert (PI) notices?

The RSC Safety Information Center (RIC) cannot add recipients for safety information that do not have a role defined by the DAIDS-approved distribution algorithm. Per DAIDS procedures, the safety information is distributed to CTU Principal Investigators, CRS Site Leaders, Investigators of Record and CTU/CRS Coordinators only, as identified in Master Contact. If individuals assigned to these roles at the site change, contact the Office of Clinical Site Oversight (OCSO) representative for that site who can have that change made. Any personnel changes to authorized recipients for NICHD funded sites need to be made through Westat.

The distribution of safety information is drug and study site specific so it is not possible for the RSC to add individuals who are not associated with the roles identified above. There are, however, ways in which rules can be created in Microsoft Outlook which will automatically forward documents received from a particular address (such as the RSC Safety Information Center) to others at your site. Other e-mail systems have similar capabilities. The IT Support group at your institution can probably assist you. Here are a few helpful links for Microsoft Outlook to create rules which will assist you in the distribution of the e-mailed documents within your site:

Microsoft Outlook support site: https://support.microsoft.com/en-us/kb/829918

Is there any way to separate protocols in development from active protocols for safety report distribution?

The DAIDS-approved distribution algorithm for safety reports (Safety Memos, IND Safety and MedWatch Reports) includes protocols that are in development. This enables DAIDS to provide relevant safety information to the DAIDS Medical Officers and Protocol Team during the development of new protocols. Per DAIDS, until the site is registered to a protocol, the site is not responsible for sending reports related to the protocol to the Institutional Review Board (IRB).

How is the electronic Investigator’s Brochure (IB) distributed?

Due to the confidential nature of the document, DAIDS distributes the IB to the CRS Leader of the applicable site. Per DAIDS procedures, IBs are sent electronically to CRS Leaders at sites participating in the study and the document should only be shared with staff directly involved in the study. The CRS Leader can access the IB via a NIAID Clinical Research Management (NCRMS) interface.

What should I do after I receive an email notification that an IB for a Version 1.0 protocol is now available?

If you receive a notification of a V1.0 IB distribution and will be participating in the study, send in your request to RIC within 3 business days. Any requests received after 3 business days will result in a delay in receiving the IB, which will be processed within 5 business days of the request. For more details please refer to FAQ on “How do I request an electronic Investigator's Brochure (IB)?” below.

Who should acknowledge the electronic Investigator’s Brochure (IB)?

Due to the confidential nature of the document, the CRS Leader should acknowledge the IB by either accepting or declining the confidentiality agreement. The CRS leader will either accept or decline the IB. The IB will not be visible until the acknowledgment has been accepted by the CRS leader. If the CRS leader declines, then the IB will not appear.

Why don’t I see an Investigator’s Brochure (IB) document in the NCRMS interface?

Only the IBs distributed from the launch of the program (September 17, 2018) will be available and displayed through the interface. All IB documents distributed prior to the launch were distributed to the CRS Leaders on CD and should be maintained at the site. If an IB document cannot be located at the site, a request for the IB will need to be sent to RIC. See the FAQ on requesting an IB “How do I request an electronic Investigator's Brochure (IB)?” below.

I see the IB record in the NCRMS interface, but I don’t see the PDF icon and I can’t open the documents.

Please note that if an IB is declined then the hyperlinks will not be available. If the CRS Leader selects the “decline” option when acknowledging the IB, the documents are not accessible. Once the CRS Leader makes this selection, it cannot be changed. You will need to contact DAIDS RSC RIC (RIC@tech-res.com) to request another IB. See FAQ “How do I request an electronic Investigator's Brochure (IB)?” below.

What should I do if I accidently decline an IB that I need access to?

You will need to contact the DAIDS RSC RIC to request the IB. In your request, please include the name of the IB, the protocol it supports, your site number, CRS Leader’s name and the reason you need the IB (i.e., you accidently declined the acknowledgment). Please send this information to the RIC (RIC@tech-res.com).

How do I request an electronic Investigator's Brochure (IB)?

Send a request via e-mail to the RIC (RIC@tech-res.com). Include the following information:

  • Name of the Investigator’s Brochure
  • Protocol Number the IB supports
  • Your site number and site name
  • Name of the CRS Leader

An email notification with access to the document will be sent within 5 business days of the request receipt. If you have not received the document within 8 business days of the request, contact the RIC via phone @ 301-897-1708 to confirm your request has been received and processed.

Note: Per DAIDS policies, only the CRS Leader can receive the IB due to the confidential nature of the document.

Do I need to submit this safety information to my Institutional Review Board (IRB)?

DAIDS cannot dictate to the sites what information needs to be submitted to individual IRBs. Sites should follow local IRB procedures regarding safety information.

How do I get safety information that was distributed prior to my site registration date?

DAIDS has indicated that sites are only required to have on file the safety reports that have been distributed since their registration to the protocol. Sites are not required to have all of the reports which have been distributed since the protocol was initiated.

What changes can I look for once a Package Insert (PI) update has been posted on the RSC website?

The PI is obtained directly from the drug company. As such, the RSC cannot comment on any changes in the document provided by the drug company. The newer PIs now have a “highlights of prescribing information” section at the beginning of the PI. Included in the highlights section is a listing of sections that have “recent major changes”. Please note that as of February 1, 2012 a Pilot program is in place to provide sites with changes made to updated PIs. Please see FAQs 15 and 16 for further information on this Pilot program.

In the cover memo for Safety Memos, it states that the information must be sent to the Institutional Review Board (IRB) within 30 days. Our IRB policy has a different timeframe. Whose instructions should we follow?

DAIDS has indicated that the site should follow local IRB/EC policy in submitting the safety reports as specified in the cover memo. If the IRB requires that the reports be submitted within a different timeframe, the site should follow the requirements of their IRB.

How do I handle Institutional Review Board (IRB) questions regarding an adverse event distributed in a Safety Memo?

An adverse event distributed as part of a Safety Memo is an event that has occurred in a drug company sponsored trial. If a site receives a question regarding an event that was distributed by DAIDS as a Safety Memo, contact the RSC Safety Information Center (RIC) with the question. RIC will forward the question to the relevant drug company. The site should receive a response directly from the drug company.

For Package Inserts (PI), will all prescribing information for human drug and biological products be required to conform with the new content and format requirements?

No. The new requirements only apply to new and recently approved prescription drugs. This includes those that were approved on or after the effective date of the Final Rule, drugs that have been approved in the 5 years prior to the effective date of the Final Rule, and older drugs for which there is a major change in the prescribing information (e.g., approval of a new use). Many older approved drug products are not required to meet the content and format revisions, though they may have to provide additional patient information. They can voluntarily revise their prescribing information. (Note: This information was taken directly from the FDA’s website. The Final Rule was published in January 2006 and became effective on June 30, 2006.) https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm

How do I check to confirm that I have received all of the safety information?

The RIC distributes a monthly report via e-mail (in excel format) listing all of the safety information which has been distributed for a year (i.e., the monthly mailer sent in July will contain information from July 1 of the previous year through June 30) by the 10th of each month. This report can be sorted by protocol to compare documents that have been received with documents that have been distributed. If you are missing a report, contact the RIC (RIC@tech-res.com). If you have not received the monthly report by the 10th of the month, contact the RIC.

What can I do if a PDF document is difficult to read when it is printed?

To enlarge and print parts of the document:

  1. Open the PDF
  2. On the toolbar, select “Tools”
  3. Go to “select and zoom”
  4. Go to “snapshot tool”
  5. Highlight the limited area on the document you wish to print
  6. Print preview: should say “selected graphic and fit to printable area”
  7. Print

How do I interpret the comparison document associated with a Package Insert (PI)?

​The document was generated using the Adobe Acrobat 9 compare documents function, and shows the text from the updated PI Version with three types of updates noted.

Note: Formatting updates are not shown in the comparison document.

  • Inserted text is underlined.
  • Replaced text (text was deleted and text was added) is highlighted. Replacements also have a number associated with them that correlates with a comment on the comments list.
  • Deleted text is displayed as strikethrough. The number correlates to a comment on the comments list.

For details on how to run your own document comparison, please refer to Adobe help links such as https://helpx.adobe.com/support/acrobat.html

Why did I not receive a document which shows the modifications made in the updated PI?

A document will only be provided if a prior version of the PI was posted to the DAIDS RSC website.

How do I Use the Monthly Comprehensive Safety Distribution Report?

For detail on the answer of this question, please refer to FAQ for Monthly Comprehensive Report

What is the potential issue if I have role of Site Leader, Site Coordinator, CTU Leader, CTU Coordinator or Investigator of Record but I don't receive safety mailer even though the RIC has confirmed that document has been sent to my e-mail address?

A potential problem could be the settings on your e-mail filters. Your e-mail filter must allow you to receive e-mail traffic from CRMSsupport@niaid.nih.gov. Check with your IT Department.

Content last reviewed on 
September 25, 2018